Effective prophylaxis against specific infections has allowed increasingly potent conditioning regimens to be given, thereby prolonging survival in HSCT recipients. The Centers for Disease Control and Prevention, in collaboration with numerous professional societies, has recently published guidelines to codify and advance this approach. Controversy remains in several areas but, curiously, the most intense debate concerns prevention of bacterial infections, the most extensively studied of all of the approaches. Clinicians have long sought a means of preventing infections among those receiving hematopoietic stem cell transplantation (HSCT). Although advances have been made in preventing certain infections such as Pneumocystis carinii and Candida albicans, 1 prevention of bacterial infections arising from routine enteric flora, which contribute a substantial amount of infectious morbidity, has been more difficult.
Clinicians have long sought a means of preventing infections among those receiving hematopoietic stem cell transplantation (HSCT). Although advances have been made in preventing certain infections such as Pneumocystis carinii and Candida albicans, 1 prevention of bacterial infections arising from routine enteric flora, which contribute a substantial amount of infectious morbidity, has been more difficult.
This review will consider both sides of the ongoing argument on optimal management: the noble goal of briefer and fewer hospitalizations with less mortality vs the inevitable consequence of antibiotic use: drug resistance.
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Oral prophylaxis: background and rationale
For decades, various approaches have been tried in an attempt to reduce the risk of translocated oral and bowel flora, which, along with central venous catheters, are the source of the overwhelming majority of episodes of serious bacterial infection in the cancer and HSCT patient. The goal is an important one and the intervention seems simple: just knock out the bowel and mouth flora with antibiotics. To this end, numerous regimens through the years have been tried, included neomycin and polymyxin, trimethoprimsulfamethoxazole and, most recently, the oral quinolones, particularly ciprofloxacin. [2] [3] [4] Despite the logic of reducing bowel and mouth flora with antibiotics, thereby reducing the risk of subsequent bacteremia, there is no consensus that this is the right thing to do. [5] [6] [7] [8] Preliminary work has even suggested that ciprofloxacin without metronidazole given as prophylaxis might promote development of graft-versus-host disease 9 and that ciprofloxacin alone may be associated with an increased risk of leukemia relapse among HSCT recipients. 10 In general, the infectious disease community, citing the concern of promoting drug resistance, has been hesitant about making this a routine approach, while the oncology community, with a specific patient in front of them whom they are trying to keep out of the hospital, has been more enthusiastic.
What then is the evidence for routine use of oral antibacterial prophylaxis? A well-conducted meta-analysis of trials using ciprofloxacin as the agent of choice for prophylaxis of patients with neutropenia was published in 1996. 2 The authors compared trials of various quinolones vs another prophylactic treatment (trimethoprim-sulfamethoxazole, non-absorbable agents, or placebo). In all, results from 2112 patients were included, representing 19 studies.
The authors found that, as hoped, the rate of Gram-negative bacteremias was reduced. Furthermore, unlike many other reports, there was no evidence for an increase in Gram-positive bacteremias. Both of these findings are exciting and important. Furthermore, in general, most clinicians believe their patients benefit from therapy.
That was the good news. The more problematic finding was that neither days with fever nor patient mortality was reduced. In other words, the intervention successfully lowers risk for certain types of bacteremia, some of them extremely serious, but, in the final analysis, has very little positive impact on the patient's overall health or survival.
A more recent meta-analysis examining a comparable group of studies reached a similar and perhaps even more cautious conclusion. 3 In this report, which included 1408 subjects from 18 studies (some included in the first metaanalysis), the authors found a reduction in infection-related outcomes but no difference in mortality. Furthermore, the difference in fever-days was modest overall and non-existent in blinded studies.
Not only that, the authors voiced a concern about the long-term consequences of such an approach: not necessarily to the actual patient at hand, but to future patients. Specifically they raised the specter of drug resistance resulting from unchecked antibiotic use. As they concluded, the emergence of resistant bacteria 'threatens to undermine the long-term efficacy of prophylaxis with fluoroquinolones'.
Resistant bacteria are only one of several real concerns arising from the practice of routinely prescribing oral agents to prevent bacterial infections. Also important to consider are other unintended consequences of this approach, each of them with potentially deleterious effects not just to the current group of patients being treated with HSCT, but those who will require this treatment in the coming years (Table 1) . Although the practice of oral prophylaxis is all but routine in many HSCT centers, the current problems with drug resistance may force a careful reconsideration of this still unproved approach.
Clinical situations with clear risk from a predictable and easily prevented organism, such as Streptococcus pneumoniae in patients with chronic GVHD, lie outside the debate. 1 In this example, the consequences of no intervention far outweigh those arising from chronic penicillin therapy and prophylaxis must be given.
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Emergence of drug resistance
Gram-negative organisms
Within months of the first doses of streptomycin, given for tuberculous meningitis in the 1940s, came reports of Table 1 Arguments for and against use of routine prophylaxis to prevent bacterial infections among HSCT recipients tuberculosis strains resistant to streptomycin. A similar phenomenon occurred when penicillin was introduced into hospitals in the 1950s: Staphylococcus aureus quickly developed resistance and rendered the drug useless in this therapeutic context. And so within moments after the widespread introduction into practice of that great twentieth century miracle -antibiotics -the bitter irony of drug resistance was born.
Arguments in favor Arguments against
The two basic tenets governing this unfortunate circumstance are simple and unalterably true: (1) the bacteria, sooner or later, will always prevail, given their vast numbers; (2) the more antibiotic given, the faster resistance emerges.
The fate of Escherichia coli susceptibility is quite telling in this regard 11 ( Table 2 ). E. coli is the most common Gram-negative bacterium causing bacteremia among neutropenic hosts in most series. Researchers from the EORTC followed the fate of E. coli as quinolone use was introduced into common practice in Europe. They identified two important consequences. First, the prevalence of resistant E. coli rose quickly during the 11-year study period (from none to 28% resistance), which was hardly a surprise. Second, and more unexpectedly, the rate and resistance pattern to the quinolones of coagulase-negative Staphylococcus increased sharply as well, from none to 61% resistance. This demonstrated that, in addition to the desired (and undesired) effect of an intervention, any change in approach may exert an unintended influence, in this case on an 'innocent bystander' pathogen that has emerged as the most common cause of catheter-related bacteremia. This is discussed in more detail below under 'unexpected pathogens'.
Vancomycin-resistant Enterococcus
The E. coli data alarmed some but not all practitioners. For many, the threat of emergent drug resistance, similar to the threat of military bioterrorism, was considered the result of the overheated imagination of the infectious disease/infection control community. Yet this dark fear became everyone's collective nightmare in the 1990s with the rapid appearance internationally of vancomycin-resistant Enterococcus (VRE). 12 Few hospital-based infections have had a more profound impact on transplant and infection control units than this pathogen. It has proven difficult to treat and, even with more and more effective agents, VRE remains a cause for tremendous alarm when it appears on any in-patient ward. How did this epidemic happen? Although numerous studies have yielded different explanations, inevitably the root cause is overuse and misuse of vancomycin. Subsequent spread via traditional nosocomial pathways then dramatically amplified its presence.
VRE now stands as the very 'poster child' of antibiotic overuse, yet its devastating presence has taught very little in terms of preventing the next nosocomial outbreak. The next bacterium might be a vancomycin-resistant strain of Staphylococcus, a Pseudomonas aeruginosa resistant to all antibiotics but polymixin, or yet another pathogen, but it is sure to have comparable consequences.
As important as the demonstration that bad things can happen to good hospitals, the emergence of VRE also showed the fundamental folly in the premise that somehow scientists can forever keep a step ahead of the bacteria. Infectious disease specialists have little or no faith in science in this race and oncologists should become equally pessimistic. As always, no sooner has a 'wonder drug' such as linezolid been approved than the inevitable converse of antibiotic potency, drug resistance, is reported. 13, 14 Thus, empiric use of vancomycin should be sharply restricted to those few centers with a large problem with Streptococcus viridans or other agents that may cause rapid death. 1, 15 Widespread, empiric use would almost certainly cause more harm than it would ameliorate: one pathogen (S. viridans) would simply be traded for the next (VRE). Importantly, the relatively low virulence of coagulase-negative Staphylococcus allows clinicians some time to establish the optimal antibiotic regimen with minimal adverse clinical consequence.
Unexpected pathogens
As mentioned above, an unanticipated consequence of antibiotic use is the emergence of unexpected pathogens. It is one thing to influence the drug susceptibility profile of the Bone Marrow Transplantation intended bacteria; it is quite another to somehow fundamentally alter which bacteria dominate in the cancer setting. A vivid example of this is S. viridans, which emerged in many cancer centers soon after the introduction of widespread use of quinolone prophylaxis. [16] [17] [18] [19] Such a result might have been anticipated, given the prevalence of S. viridans in normal oral mucosa and the relative inactivity of the quinolone class, including the newer agents, against this pathogen.
Several reports from the early 1990s described the emergence of S. viridans. At MD Anderson, the rate of S. viridans bacteremia rose from 1/10 000 to 47/10 000 admissions. 16 The increase was associated with use as prophylaxis of either trimethoprim-sulfamethoxazole or ciprofloxacin. The investigators also described a shock-like syndrome from the organism, which previously had seldom been encountered. 16 The disease resembled toxic shock and was characterized by hypotension, rash, palmar desquamation, and adult respiratory distress syndrome. The infection was fatal in 26% of patients. Subsequent reports from other groups have verified that S. viridans can indeed cause a shock-like illness. In addition, use of ara-C (cytosine arabinoside) 17 or cyclophosphamide 18 has been shown to be associated with development of S. viridans, presumably due to the increased intensity of oral mucositis associated with these chemotherapeutic agents.
Thus the short-term gain afforded by quinolone use was in danger of being overtaken by the delayed consequence of the approach: a new organism that could cause shock with high mortality rates and, by coincidence, was itself becoming increasingly resistant to such first-line agents as penicillin. 20 A related phenomenon is the emergence of environmental organisms of modest pathogenic capacity, such as Stenotrophomonas maltophilia 21 and Acinetobacter species. 22 These organisms have established a foothold in various intensive care units because they are resistant to the common potent antibiotics used for the very ill, such as imipenem or the third-generation cephalosporins. The result of this type of antibiotic overuse is infestation to the point of endemicity in numerous ICUs of tenacious, drug-resistant bacteria that are a particular risk to the already compromised, such as those receiving HSCT. Once they establish their ecosystem in an ICU, it is very difficult to get them out, since they thrive in tepid water, respirator tubing, as well as on inanimate surfaces, such as tabletops and bed guardrails. Prevention of these bacteria is far easier than treatment, underlining again the need for a disciplined program of antibiotic control and will-power against the seductions of immediate broad-spectrum activity. Awareness of potential long-term consequences should inform all antibiotic decision-making. A final example of the dangers of disturbing normal host flora, unless necessary, was demonstrated in a study that examined VRE density as a function of anti-anaerobic antibiotic use. 23 Investigators found that anti-anaerobic antibiotics appeared to promote high-density VRE colonization that in turn was associated with a higher likelihood of VRE transmission. Thus, antibiotics used to prevent a first infection may inadvertently lead to development of a second and even more serious condition.
The optimal approach to prevention and control of VRE continues to develop. New investigational non-absorbed antibiotics such as ramoplanin offer one potential approach, while other centers routinely screen all HSCT pre-transplant and on re-admission to identify VRE carriers. One center both screens and quantifies the amount of VRE to better determine patient risk for invasive disease, as well as the influence of various antibiotics on VRE carriage (R Bonomo and M Lisgaris, personal communication).
Subsequent antibiotic choices
In addition to promotion of drug resistance and a distortion of the hospital spectrum of anticipated agents towards more tenacious and perhaps more virulent replacements, the indiscriminate use of the quinolones has a potentially deleterious effect on subsequent antibiotic choices. Patients receiving quinolones as prophylaxis who then develop neutropenia and fever (and fever episodes in most studies are not decreased by quinolone prophylaxis) must be hospitalized for intravenous antibiotics. However, these patients should not receive quinolones in management of their neutropenic fever on the assumption that the infection has 'broken through' the prophylaxis. Thus, an entire class of agents is removed from the treating team's armamentarium. Table 3 Recommendations for use of bacterial prophylaxis in HSCT This is particularly problematic among cancer and transplant patients. These individuals are hospitalized repeatedly and for protracted periods, often requiring prolonged courses of multiple antibiotics. Drug allergy and intolerability are at least as common in the cancer or transplant patient as the general population, in whom up to 25% report allergies to at least one agent. 24 Thus, for the beta-lactam allergic patient, removal of the quinolone class as a potential option relegates choices to the more toxic, such as the aminoglycoside class and/or an agent such as vancomycin, which may itself promote drug resistance. Preserving the option of quinolone use is a worthy goal for management of such patients.
Summary and recommendations
Bacterial infections, although perhaps less dramatic or intellectually stimulating as their viral and fungal counterparts, continue to account for significant morbidity and mortality in HSCT recipients. Furthermore, the possibility of preventing these complications seems uncharacteristically simple. The common pathogens are known; numerous oral agents are active against them, and patients usually can tolerate the medications. What then is the problem?
As discussed above, the long-term consequences of routine bacterial prophylaxis are beginning to emerge and are causing significant concern in the infectious disease community. Rising rates of resistance, emergence of unexpected pathogens, and loss of quinolones in the treatment of fever and neutropenia all argue strongly for containment of routine use. That said, there remains a significant need for such agents in certain situations. Patient comfort and confidence are extremely important issues, particularly over the long haul of cancer chemotherapy or HSCT.
One approach would be to use oral prophylaxis cautiously, restricting its use to the highest risk patients (Table  3) . These include persons with previous serious Gramnegative infection, such as ecthyma gangrenosum from Pseudomonas aeruginosa. In addition, those with known predictable immune defects, such as the propensity for persons with chronic GVHD to develop invasive Streptococcus pneumoniae, should receive prophylaxis. Prophylaxis might also be carefully considered for older patients and those with significant co-morbidities. Although this parsimonious approach flies in the face of current practice and will be uncomfortable in the near term, the ultimate consequences of using less oral prophylaxis will benefit current and future HSCT recipients.
